ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial

Latest data for managing ALK NSCLC patients

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

ASH 2020: Targeted therapies in r/r multiple myeloma

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation